Metastatic Castration-resistant Prostate Cancer Clinical Trials

42 studies are recruiting for metastatic castration-resistant prostate cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. The COSMYC Trial (COmbined Suppression of MYC)

   This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigato…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06922318 on ClinicalTrials.gov

2. Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

   The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   Syntrix Biosystems, Inc.

   See if you can join NCT06228053 on ClinicalTrials.gov

3. Study With [225Ac]Ac-FL-020 in mCRPC Participants

   The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of [225Ac]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   11 in total

   Run by

   Full-Life Technologies UK Limited

   See if you can join NCT06492122 on ClinicalTrials.gov

4. A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

   This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Sarasota, Florida

   Locations

   6 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07189403 on ClinicalTrials.gov

5. A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

   This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Diego Moores Cancer Center, La Jolla, California

   Locations

   19 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07244341 on ClinicalTrials.gov

6. Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

   The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT07476001 on ClinicalTrials.gov

7. Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

   To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Biogenix Molecular LLC, Miami, Florida

   Locations

   21 in total

   Run by

   Blue Earth Therapeutics Ltd

   See if you can join NCT05413850 on ClinicalTrials.gov

8. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

   The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Miami, Florida

   Locations

   16 in total

   Run by

   AstraZeneca

   See if you can join NCT06879041 on ClinicalTrials.gov

9. ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

   This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. Th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   California Research Institute, Los Angeles, California

   Locations

   31 in total

   Run by

   Zenith Epigenetics

   See if you can join NCT04986423 on ClinicalTrials.gov

10. A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

    This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University Medical Center - Blake Wilbur Drive, Palo Alto, California

    Locations

    14 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05125016 on ClinicalTrials.gov

11. Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

    This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation phase and dose-expansi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06193486 on ClinicalTrials.gov

12. 64Cu-GRIP B in Patients With Advanced Malignancies

    This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patie…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Rahul Aggarwal

    See if you can join NCT05888532 on ClinicalTrials.gov

13. Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

    The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect o…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT07142551 on ClinicalTrials.gov

14. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Los Angeles Cancer Network, Anaheim, California

    Locations

    25 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT04729114 on ClinicalTrials.gov

15. Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

    The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06099093 on ClinicalTrials.gov

16. A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

    The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with P…

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    University of California LA, Los Angeles, California

    Locations

    21 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06531499 on ClinicalTrials.gov

17. Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

    The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patie…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Excel Diagnostics & Nuclear Oncology Center, Houston, Texas

    Run by

    Ebrahim S Delpassand

    See if you can join NCT06972628 on ClinicalTrials.gov